Replicel Life Sciences Inc., of Vancouver, British Columbia, completed the second tranche of a financing initiated in March, consisting of a non-brokered private placement of 737,000 units priced at 75 cents apiece for proceeds of $552,750, raising total gross proceeds from the offering to approximately $3.3 million. Each unit included one common share and one warrant to purchase an additional share for a period of up to two years at $1 apiece during the first year and $1.25 apiece during the second year. The company expects a third closing under the same terms.